Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTR101 in Sarcopenia Patients
NCT06788236Phase 2Terminated
- Sponsor
- Aventi
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AVTR101 in Sarcopenia (2 arms), sponsored by Aventi. Primary endpoint: Short Physical Performance Battery at 12 weeks. Started May 2022; status: terminated.
02
Drugs
AVTR101
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT06788236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788236.